Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy.

Brain tumor pathology - 1 Apr 2024

Sasaki Hikaru, Kitamura Yohei, Toda Masahiro, Hirose Yuichi, Yoshida Kazunari

Abstract excerpt

Oligodendroglioma, IDH-mutant and 1p/19q-codeleted is known for their relative chemosensitivity and indolent clinical course among diffuse gliomas of adult type. Based on the data from phase 3 clinical trials, the standard of post-surgical care for those tumors is considered to be initial chemoradiotherapy regardless of histopathological grade, particularly with PCV. However, partly due to its renewed definition...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Chromosome Deletion

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 1

Share to Chromosomes, Human, Pair 19

Share to Isocitrate Dehydrogenase

Share to Neoadjuvant Therapy

Share to Oligodendroglioma

Share to Survival Rate

Source

Identifiers

PMID: 38564040
DOI: 10.1007/s10014-024-00480-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy.PMID 38564040Read ↗

Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomasSemantic proximity Read ↗

[Oligodendroglioma, IDH Mutation and 1p/19q Codeletion].Semantic proximity Read ↗

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.Semantic proximity Read ↗

Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.Semantic proximity Read ↗

Oligodendroglioma: pathology, molecular mechanisms and markersSemantic proximity Read ↗

Survival outcome and prognostic factors in anaplastic oligodendroglioma: a single-institution study of 95 cases.Semantic proximity Read ↗

Predictive and prognostic factors for gliomas.Semantic proximity Read ↗

Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.Semantic proximity Read ↗

IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy.Semantic proximity Read ↗

Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?Semantic proximity Read ↗

Thirty years of progress in the management of low-grade gliomas.Semantic proximity Read ↗

Treatment recommendations for anaplastic oligodendrogliomas that are codeleted.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.